All In Biotech

Drug Trial Radar · NCT00418522

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

A Six Month, Open Label, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 413 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

413

Actual

Start

Mar 2007

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin glargineDrug

    Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

  • Inhaled Insulin (Exubera)Drug

    Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) PopulationTime frame: Baseline, Week 26

Locations

73 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Phoenix, Arizona

  • Pfizer Investigational Site

    Tucson, Arizona

  • Pfizer Investigational Site

    Concord, California

  • Pfizer Investigational Site

    Encino, California

  • Pfizer Investigational Site

    Fresno, California

  • Pfizer Investigational Site

    Fullerton, California

  • Pfizer Investigational Site

    Long Beach, California

  • Pfizer Investigational Site

    Mission Viejo, California

  • Pfizer Investigational Site

    Pasadena, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Diego, California

  • Pfizer Investigational Site

    San Luis Obispo, California

  • Pfizer Investigational Site

    Spring Valley, California

  • Pfizer Investigational Site

    Stockton, California

  • Pfizer Investigational Site

    Walnut Creek, California

  • Pfizer Investigational Site

    West Hills, California

  • Pfizer Investigational Site

    Golden, Colorado

  • Pfizer Investigational Site

    Waterbury, Connecticut

  • Pfizer Investigational Site

    Newark, Delaware

  • Pfizer Investigational Site

    Chiefland, Florida

  • Pfizer Investigational Site

    Clearwater, Florida

  • Pfizer Investigational Site

    Hollywood, Florida

  • Pfizer Investigational Site

    Kissimmee, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Ocala, Florida

  • Pfizer Investigational Site

    Saint Cloud, Florida

  • Pfizer Investigational Site

    Winter Park, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Lawrenceville, Georgia

  • Pfizer Investigational Site

    Lawrenceville, Georgia

  • Pfizer Investigational Site

    Woodstock, Georgia

  • Pfizer Investigational Site

    Boise, Idaho

  • Pfizer Investigational Site

    Hayden Lake, Idaho

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Overland Park, Kansas

  • Pfizer Investigational Site

    Topeka, Kansas

  • Pfizer Investigational Site

    Lexington, Kentucky

  • Pfizer Investigational Site

    Louisville, Kentucky

  • Pfizer Investigational Site

    Baton Rouge, Louisiana

  • Pfizer Investigational Site

    New Orleans, Louisiana

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.